Dr. Rosalia Rutter

An update of the CheckMate 204 trial confirms efficacy and safety of first-line nivolumab/ipilimumab in patients with untreated asymptomatic melanoma brain metastases, and for the first time intracranial antitumor activity in symptomatic patients.

Growing evidence raises hopes for neoadjuvant checkpoint inhibition in early NSCLC. At ESMO 2018, exciting new preliminary phase II data from the NEOSTAR trial have emerged supporting this concept.